US FDA approves Ionis Pharma's therapy to treat rare brain disorder

The U.S. FDA approved Ionis Pharmaceuticals’ therapy for a rare genetic brain white-matter disorder, marking the first treatment to receive approval for the condition. The “first-in-class/first-approved” status is a major regulatory catalyst that should improve the drug’s commercial outlook and investor sentiment.